Home > Insider Trading > Filing (0001209191-16-088749)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
827871	Eagle Pharmaceuticals Inc.	EGRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1469124	Scott Tarriff	C/O Eagle Pharmaceuticals, Inc. 50 Tice Blvd., Suite 315 Woodcliff Lake NJ 07677	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-01-04	11,776	$85.65	1,441,624	No	4	S	Direct
Common Stock	Disposition	2016-01-04	2,773	$87.02	1,438,851	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2016-01-04	180,000	$0.00	180,000	$86.15

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
180,000		2026-01-03	No	4	A	Direct

Footnotes

These shares were sold pursuant to a Rule 10b5-1 trading plan dated as of June 19, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.37 to $86.12, inclusive. The reporting person undertakes to provide to Eagle Pharmaceuticals, Inc., any security holder of Eagle Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) and in footnote (3).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $86.50 to $87.185, inclusive.
The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 4, 2017, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.